April 6, 2015 / 11:50 AM / 3 years ago

BUZZ-Curis Inc: Orphan status for lead cancer drug

** Drug developer’s shares up 10.63 pct at $2.60 premarket

** Says the U.S. FDA has granted orphan status for its lead cancer drug, CUDC-907

** Says drug being tested in early-stage studies; expects to begin mid-stage studies in second half of year

** Orphan status, which is granted to drugs developed to treat rare diseases, gives developer several incentives including a seven-year marketing exclusivity in U.S.

** Up to Thursday’s close, stock had risen 57 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below